179 related articles for article (PubMed ID: 35041152)
1. Multi-time scale transcriptomic analysis on the dynamic process of tamoxifen resistance development in breast cancer cell lines.
Zeng Q; Lin X; Chen H; Yan Y; Wang X
Breast Cancer; 2022 May; 29(3):458-467. PubMed ID: 35041152
[TBL] [Abstract][Full Text] [Related]
2. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
[TBL] [Abstract][Full Text] [Related]
3. Role of β1-integrin in promoting cell motility and tamoxifen resistance of human breast cancer MCF-7 cells.
Hu S; Yang Q; Chen Z; Fu W
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e223-e230. PubMed ID: 36065151
[TBL] [Abstract][Full Text] [Related]
4. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells.
Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA
Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S
J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803
[TBL] [Abstract][Full Text] [Related]
7. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
8. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
Jan R; Huang M; Lewis-Wambi J
Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.
Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE
Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025
[TBL] [Abstract][Full Text] [Related]
12. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.
Zhou C; Zhong Q; Rhodes LV; Townley I; Bratton MR; Zhang Q; Martin EC; Elliott S; Collins-Burow BM; Burow ME; Wang G
Breast Cancer Res; 2012 Mar; 14(2):R45. PubMed ID: 22417809
[TBL] [Abstract][Full Text] [Related]
13. CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.
Wu M; Soler DR; Abba MC; Nunez MI; Baer R; Hatzis C; Llombart-Cussac A; Llombart-Bosch A; Aldaz CM
Mol Cancer Res; 2007 Dec; 5(12):1285-95. PubMed ID: 18171986
[TBL] [Abstract][Full Text] [Related]
14. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
15. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
16. Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells.
Redmond AM; Byrne C; Bane FT; Brown GD; Tibbitts P; O'Brien K; Hill AD; Carroll JS; Young LS
Oncogene; 2015 Jul; 34(29):3871-80. PubMed ID: 25284587
[TBL] [Abstract][Full Text] [Related]
17. Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.
Lin X; Li J; Yin G; Zhao Q; Elias D; Lykkesfeldt AE; Stenvang J; Brünner N; Wang J; Yang H; Bolund L; Ditzel HJ
Breast Cancer Res; 2013 Dec; 15(6):R119. PubMed ID: 24355041
[TBL] [Abstract][Full Text] [Related]
18. Changes in DNA Damage Repair Gene Expression and Cell Cycle Gene Expression Do Not Explain Radioresistance in Tamoxifen-Resistant Breast Cancer.
Post AEM; Bussink J; Sweep FCGJ; Span PN
Oncol Res; 2020 Feb; 28(1):33-40. PubMed ID: 31046897
[TBL] [Abstract][Full Text] [Related]
19. Association of tamoxifen resistance and lipid reprogramming in breast cancer.
Hultsch S; Kankainen M; Paavolainen L; Kovanen RM; Ikonen E; Kangaspeska S; Pietiäinen V; Kallioniemi O
BMC Cancer; 2018 Aug; 18(1):850. PubMed ID: 30143015
[TBL] [Abstract][Full Text] [Related]
20. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer.
Jia Y; Zhou J; Luo X; Chen M; Chen Y; Wang J; Xiong H; Ying X; Hu W; Zhao W; Deng W; Wang L
Cell Signal; 2018 Jan; 42():165-175. PubMed ID: 28988130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]